← Psoriasis-overzicht

Referenties psoriasis-dossier

Dit dossier is gebaseerd op een literatuursynthese van reviews, case-control studies en mechanistische studies, met het zwaartepunt op recent werk en de Nature Reviews Disease Primers van 2025 als spilreferentie. Per claim is in de hoofdstukken de PMID vermeld. Hieronder de volledige lijst.

Overzicht, pathogenese en pathways

• PMID 40571687 - Psoriasis. Nature Reviews Disease Primers, 2025. (Spilreferentie.)
• PMID 38642273 - The Immunology of Psoriasis: Current Concepts in Pathogenesis. Clinical Reviews in Allergy & Immunology, 2024.
• PMID 41869364 - Psoriasis: microbiome dysbiosis and pathogenic mechanisms. Frontiers in Immunology, 2026.
• PMID 41939652 - Peroxisome Proliferator-Activated Receptors (PPARs) in Psoriasis: Metabolic Intersections, Molecular Mechanisms, and Potential Treatments. Cureus, 2026.
• PMID 40537849 - Psychological Stress Overactivates IL-23/Th17 Inflammatory Axis and Increases cDC2 in Imiquimod-Induced Psoriasis Models of C57BL/6 Mice. Experimental Dermatology, 2025. (Muismodel.)

Genetica en epigenetica

• PMID 19818216 - The genetics of psoriasis: selected novelties in 2008. Acta Dermatovenerologica Croatica, 2009.
• PMID 32955211 - Environmental risk factors and epigenetic alterations in psoriasis. Annals of Agricultural and Environmental Medicine, 2020.
• PMID 30591370 - Identification of a natural inhibitor of methionine adenosyltransferase 2A regulating one-carbon metabolism in keratinocytes. EBioMedicine, 2019.
• PMID 18355300 - The methylenetetrahydrofolate reductase 677C>T gene polymorphism is not associated with chronic plaque psoriasis. Experimental Dermatology, 2008.
• PMID 22217364 - Association of MTHFR 677 C>T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study. Nutrition Journal, 2012.
• PMID 24753765 - Methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis. International Journal of Clinical and Experimental Medicine, 2014.

Risicofactoren

• PMID 29723384 - Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis (n=563). Anais Brasileiros de Dermatologia, 2018.

Suppletie, lifestyle en natural compounds

• PMID 40899030 - Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy. Phytotherapy Research, 2025.
• PMID 41447846 - Biological activity study of a pine pollen extract rich in dihydroquercetin for the treatment of psoriasis. Phytomedicine, 2026. (Muismodel.)
• PMID 41785726 - Integrating network pharmacology and experimental validation to elucidate the mechanism of Xiao-bi decoction in psoriasis treatment: Inhibition of JAK2/STAT3 signaling and rebalancing Th17/Treg responses. Journal of Ethnopharmacology, 2026. (Muismodel.)
• PMID 17538801 - Folic acid in general medicine and dermatology. Journal of Dermatological Treatment, 2007.

Medicatie en methylatie-nuance

• PMID 35956194 - MTHFR Polymorphism and Folic Acid Supplementation Influence Serum Homocysteine Levels in Psoriatic Patients Treated with Methotrexate. Journal of Clinical Medicine, 2022.
• PMID 8765212 - DNA hypomethylation in inflammatory arthritis: reversal with methotrexate. Journal of Laboratory and Clinical Medicine, 1996.

Comorbiditeit

• PMID 29928910 - Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology, 2019.
• PMID 37184282 - Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation. Journal of the European Academy of Dermatology and Venereology, 2023.

Disclaimer

Dit dossier is een samenvatting van wetenschappelijke literatuur ten behoeve van professionals en geïnformeerde gebruikers. Lees het als naslag, geen medisch advies en geen vervanging van een individueel consult, een diagnose of een behandeling. Stem beslissingen over medicatie, suppletie of leefstijl per persoon af met de betrokken zorgverleners.